SI
Highly rated in
8
conditions
Highly rated in
8
conditions
Check Dr. Susan T. Iannaccone's experience treating your condition:
About Dr. Susan T. Iannaccone

Susan Iannaccone is a Neurologist and a Pediatrics expert in Dallas, Texas. Iannaccone has been practicing medicine for over 53 years and is highly rated in 8 conditions, according to our data. Her top areas of expertise are Spinal Muscular Atrophy SMA, Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, and Spinal Muscular Atrophy Type 3. She is licensed to treat patients in Texas. Iannaccone is currently accepting new patients.

Her clinical research consists of co-authoring 67 peer reviewed articles and participating in 4 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Susan T. Iannaccone it is best to call her office and ask if your insurance is accepted.


Dr. Susan T. Iannaccone accepts the following insurance:

  •  Ambetter

Call to see if your plan is accepted.
Locations
2350 N Stemmons Fwy, Dallas, TX 75207
Other Locations
2350 N Stemmons Fwy, Dallas, TX 75207
1935 Medical District Dr, Dallas, TX 75235
Background & Education
Graduate Institution
State University Of New York Health Science Center Of Syracuse, 1969.0
Specialties
Neurology
Pediatrics
Child Neurology
Licenses
Psychiatry & Neurology in TX
Hospital Affiliations
Childrens Medical Center Dallas
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


4 Clinical Trials

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Extracellular RNA Biomarkers of Myotonic Dystrophy
View 2 Less Clinical Trial -

70 Total Publications

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Summary: Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors